Clin Assoc Prof Winnie Lam Wing Chuen

MBBS (Singapore), FRCR (UK), FAMS (Nuclear Medicine)

Head ＆ Senior Consultant

Singapore General Hospital

Specialty: Nuclear Medicine

Make an Appointment

About

Education and Training

Professional Appointments and Committee Memberships

Awards

Research Interests

Research Trials

Publications

Conditions Treated By This Doctor

Bone Mineral Densitometry (BMD) General Nuclear Medicine Liver Tumours Neuroendocrine Tumors Nuclear Cardiology Nuclear Oncology PET/CT Prostate Cancer Radionuclide Bone Pain Palliation Radiosynovectomy (Radiation Synovectomy / Radiosynoviorthesis) Thyroid Cancer Thyrotoxicosis Y90 Microspheres

Clinical Interests

Nuclear Medicine and Molecular Imaging, Theranostics

Clinical Appointments

Head ＆ Senior Consultant

Nuclear Medicine and Molecular Imaging

Academic Deputy Vice Chair, Clinical Service Operations, Radiological Sciences ACP

Academic Appointments

Clinical Associate Professor, Duke-NUS Medical School

Clinical Senior Lecturer, NUS Yong Loo Lin School of Medicine

Clinical Teacher, NTU Lee Kong Chian School of Medicine

About

With over a decade of specialist experience, Winnie has actively contributed to the development of novel PET imaging applications across oncology, neuroimaging, and systemic inflammatory diseases. Her leadership in education, as the inaugural Program Director of the Singapore Nuclear Medicine Residency, and her long-standing service on national training and advisory committees highlight her influence in shaping the next generation of imaging specialists. Winnie has led and participated in multiple clinical trials involving advanced molecular tracers (e.g. 18F-FET, Ga-68 FAPI, PSMA, Y-90), and her recent publications reflect strong expertise in theranostics and quantitative imaging. Her current interest will be advancing low-dose, high-sensitivity imaging platforms and guiding clinical validation in patients through her dual focus on precision diagnostics and operational excellence.

Education and Training

Fellow of the Academy of Medicine, Singapore in Nuclear Medicine
Fellow of the Royal College of Radiologists (UK)
MBBS, National University of Singapore

Professional Appointments and Committee Memberships

Member, Radiological Sciences SingHealth Executive Committee
Member, Residency Advisory Committee for Nuclear Medicine, Ministry of Health
Exco member, Clinical Trials & Research Centre

Awards

20 years Long Service Award, Singapore General Hospital 2023
Faculty Appreciation Award, Residency in SingHealth Excels (RiSE) 2019
RADSC ACP Sponsorship Award, EANM 2018
Best JCST Programme (Nuclear Medicine), Residency in SingHealth Excels (RiSE) 2018
Silver Award, Team Excellence IQC Assessment, Singapore Productivity Association 2016
Outstanding Faculty Award, Residency in SingHealth Excels (RiSE) 2014

Research Interests

Nuclear medicine
Molecular Imaging

Research Trials

AcTFirst: A phase III, open-label, multi-center, randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer - as PI
18F-FET (O-(2-[18F]fluoroethyl)-L-tyrosine) PET in differentiating tumour progression from pseudoprogression in high grade gliomas (supported by Khoo Pilot Award (Collaborative)) - as Co-Investigator
68Ga-FAPI based PET/CT for imaging Systemic sclerosis-associated Interstitial Lung Disease (SSc-ILD) (supported by SGH Research Grant) - as Co-Investigator
Outcomes of Radioiodine Therapy for Thyroid Cancer - as PI

Publications

Huang HL, Koo SX, Tang C, Tham WY, Zaheer S, Lam W, Chan JYS. Bayesian Penalized Likelihood Reconstruction Algorithm Results in Similar Prognostic Markers on FDG PET/CT in DLBCL. Hematological Oncology 2025 Jun.
Chow KM, Lee A, Peh D, Tan YG, Tay KJ, Ho H, Cheng C, Lam W, Thang SP, Tuan J, Law YM, NgoT, Khor LY, Yuen J, Eapen R, Lawrentschuk N, Hofman M, Murphy D, Chen K. Combined Prostate-specific Membrane Antigen Positron Emission Tomography and Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. European Urology Oncology 2025 Jun.
Ng CWQ, Chua WM, Lam WW, Tong AK, Ng DCE, Tang C, Tham WY, Kanesvaran R, Wong ASC, Tay KJ, Chen K, Thang SP. Safety and Efficacy of Lutetium-177 PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study). Asia Pac J Clin Oncol. 2025 May.
Koh NXY, Chua WM, Lam WW, Tong AK, Kanesvaran R, Wong ASC, Chen K, Thang SP. Prognostic [68Ga]Ga-PSMA-11 PET Biomarkers for [177Lu]Lu-PSMA Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer (Asian Population Study). Asia Pac J Clin Oncol. 2025 Aug;21(4);399-406.
Chua WM, Tang CYL, Loke KSH, Lam WW, Yang SP, Lee MS, Hou W, Lim WYS, Lim KC, Chen R. Differentiated Thyroid Cancer after Thyroidectomy. Radiographics. 2024 Oct;44(10):e240021.
Ng CWQ, Bin Hassan MJ, Goh C, Tong AKT, Tham WY, Thang SP, Lam WW, Low HC, Magsombol BM, Loke KSH. Safety and Efficacy of 90Y Selective Internal Radiation Therapy Using Glass Microspheres in Hepatocellular Carcinoma: A Southeast Asian Single-Institution Initial Experience. J Nucl Med Technol. 2024 Jun;52(2):148-151.
Chin J, Tan YG, Lee A, Ng TK, Shi R, Tang CYL, Thang SP, Tuan JKL, Cheng CWS, Tay KJ, Ho HSS, Wang H, Chiu PK, Teoh JY, Lam WW, Law YM, Yuen JSP, Chen K. “See Is Believing”: Additive Utility of 68Ga-PSMA-11 PET/CT in Prostate Cancer Diagnosis. Cancers (Basel). 2024 May;16(9);1777.
Tay WJ, Teh DJW, Qin Y, Lam WW. The Curious Case of the Missing Limb on FDG PET Imaging. Clin Nucl Med. 2024 Feb;49(2) 185-187.
Tang CYL, Chua WM, Huang HL, Lam WW, Loh LM, Tai D, Ong SYK, Yan SX, Loke KSH, Ng DC, Tham WY. Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature. J Neuroendocrinol. 2023 Dec;35(12) e13349.
Sommat K, Tong AKT, Ong ALK, Hu J, Sin SY, Lam WWC, Xie W, Khor YM, Lim C, Lim TW, Selvarajan S, Wang F, Tan TWK, Wee JTS, Soong YL, Fong KW, Hennedige T, Hua TC. 18F-FMISO PET-guided dose escalation with multifield optimization intensity-modulated proton therapy in nasopharyngeal carcinoma. Asia Pac J Clin Oncol. 2023 May .
Chua WM, Lam WW, Tong AK, Sultana R, Kua SMY, Kanesvaran R, Wong ASC, Tay KJ, Cheng TJL, Ng DCE, Thang SP. Outcomes and prognostic predictors of Lu-177 PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian Population Study). Asia Pac J Clin Oncol. 2023 Mar .
Chen M, Tang CYL, Fong WWS, Lam WW. Semi-quantitative indices of 2[18F]FDG PET/CT in assessing cardiovascular and non-cardiovascular manifestations of IgG4-related disease and treatment response. EJNMMI Res. 2023 Mar;13(1) 22.